Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Gusstoon Apr 26, 2018 2:49pm

148 Views

Post# 27945992

level 2

is starting to look pretty sweet!

Level ll Quote
Bid			Ask
Price	Total Size	# of Orders	Price	Total Size	# of Orders

$0.18	208000	11	$0.185	36500	3
$0.175	333000	19	$0.19	166500	10
$0.17	332000	26	$0.195	196500	8
$0.165	191500	13	$0.20	142000	13
$0.16	555000	23	$0.205	105000	5
$0.155	132500	11	$0.21	156000	8
$0.15	593500	22	$0.215	90000	7
$0.145	3000	2	$0.22	93500	9
$0.14	78500	7	$0.225	81500	7
$0.135	170000	8	$0.23	106000	7